ARBs may decrease risk of Dementia @ יואל קסלר
ARBs may decrease risk of Dementia @ יואל קסלר

ARBs may decrease risk of Dementia in patients with MCI @ יואל קסלר .com

In this post at ARBs may decrease risk of Dementia @ יואל קסלר .com we discuss a recently published article in the journal Hypertension, investigators presented evidence that treatment with angiotensin receptor blockers in patients with mild cognitive impairment may prevent progression to dementia. For more interesting articles check out our blog.

Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia

Zhenhong DengJingru JiangJia WangDong PanYingying ZhuHonghong LiXiaoni ZhangXiaohuan Liu Yongteng XuYi Li, Yamei Tangand for the Alzheimer’s Disease Neuroimaging Initiative†

Originally published29 Jun 2022Hypertension. 2022;0:10.1161/HYPERTENSIONAHA.122.19378



Previous studies found that antihypertensive medications (AHMs) acting on the renin-angiotensin system had the potential to reduce the progression from mild cognitive impairment to dementia. However, it remains unclear whether this association differs between ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers.


We conducted a retrospective cohort study in the Alzheimer’s Disease Neuroimaging Initiative among 403 participants with hypertension and mild cognitive impairment at baseline. Information on AHMs received during the follow-up period, including angiotensin receptor blockers, ACE inhibitors, beta-blockers, calcium channel blockers, and diuretics, were self-reported. Cox proportional hazards models adjusted for potential confounders were used in the time to event analysis with progression to dementia as outcome.


Of the 403 participants, the mean (SD) age was 74.0 (7.3) years, 152 (37.7%) were female, 158 (39.2%) progressed to dementia over a median follow-up time of 3.0 years. Angiotensin receptor blockers were associated with a lower risk of progression to dementia as compared to ACE inhibitors (adjusted hazard ratio=0.45 [95% CI, 0.25–0.81]; P=0.023), other classes of AHMs (beta-blockers, calcium channel blockers, diuretics; adjusted hazard ratio, 0.49 [95% CI, 0.27–0.89]; P=0.037), and none of AHMs (adjusted hazard ratio, 0.31 [95% CI, 0.16–0.58]; P=0.001).


In patients with hypertension and mild cognitive impairment, angiotensin receptor blockers were associated with a lower risk of progression to dementia compared with ACE inhibitors and other classes of AHMs. Our findings may have important implications for clinical practice but still warrant further investigations in larger prospective cohorts or clinical trials.

בפוסט זה ב יואל קסלר .קום אנו דנים במאמר שפורסם לאחרונה בכתב העתון היפרטנסיון , החוקרים הציגו ראיות לכך שטיפול בחוסמי קולטן לאנגיוטנסין בחולים עם ליקוי קוגניטיבי קל עשוי למנוע התקדמות לדמנציה. למאמרים מעניינים נוספים עיין בבלוג שלנו.

יואל קסלר

Interested in medical and scientific advances and innovations

%d בלוגרים אהבו את זה: